235 related articles for article (PubMed ID: 26455564)
1. Possibility of Acetylcholinesterase Overexpression in Alzheimer Disease Patients after Therapy with Acetylcholinesterase Inhibitors.
Kračmarová A; Drtinová L; Pohanka M
Acta Medica (Hradec Kralove); 2015; 58(2):37-42. PubMed ID: 26455564
[TBL] [Abstract][Full Text] [Related]
2. An update on the pharmacology of galantamine.
Villarroya M; García AG; Marco-Contelles J; López MG
Expert Opin Investig Drugs; 2007 Dec; 16(12):1987-98. PubMed ID: 18042006
[TBL] [Abstract][Full Text] [Related]
3. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
Emre M
Int J Clin Pract Suppl; 2002 Jun; (127):64-72. PubMed ID: 12139369
[TBL] [Abstract][Full Text] [Related]
4. [Acetylcholinesterase inhibitors for treatment of Alzheimer's disease].
Shinagawa S; Shigeta M
Brain Nerve; 2014 May; 66(5):507-16. PubMed ID: 24807367
[TBL] [Abstract][Full Text] [Related]
5. Acetylcholinesterase inhibitors: a patent review (2008 - present).
Pohanka M
Expert Opin Ther Pat; 2012 Aug; 22(8):871-86. PubMed ID: 22768972
[TBL] [Abstract][Full Text] [Related]
6. Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Liang YQ; Tang XC
Neurosci Lett; 2004 May; 361(1-3):56-9. PubMed ID: 15135892
[TBL] [Abstract][Full Text] [Related]
7. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of purinergic neurotransmission by galantamine and other acetylcholinesterase inhibitors in the rat vas deferens.
Caricati-Neto A; D'angelo LC; Reuter H; Hyppolito Jurkiewicz N; Garcia AG; Jurkiewicz A
Eur J Pharmacol; 2004 Oct; 503(1-3):191-201. PubMed ID: 15496314
[TBL] [Abstract][Full Text] [Related]
9. New anti-Alzheimer drugs from biodiversity: the role of the natural acetylcholinesterase inhibitors.
Viegas C; Bolzani Vda S; Barreiro EJ; Fraga CA
Mini Rev Med Chem; 2005 Oct; 5(10):915-26. PubMed ID: 16250834
[TBL] [Abstract][Full Text] [Related]
10. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs.
Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V
Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of new 2-benzoxazolinone derivatives as potential cholinesterase inhibitors for therapy of alzheimer's disease.
Szymański P; Janik A; Zurek E; Mikiciuk-Olasik E
Pharmazie; 2011 Jun; 66(6):399-403. PubMed ID: 21699076
[TBL] [Abstract][Full Text] [Related]
12. [Acetylcholinesterase inhibitors in Alzheimer's disease: further comments on their mechanisms of action and therapeutic consequences].
Nieoullon A
Psychol Neuropsychiatr Vieil; 2010 Jun; 8(2):123-31. PubMed ID: 20525543
[TBL] [Abstract][Full Text] [Related]
13. [Anticholinesterases in the treatment of Alzheimer's disease].
Gandía L; Alvarez RM; Hernández-Guijo JM; González-Rubio JM; de Pascual R; Rojo J; Tapia L
Rev Neurol; 2006 Apr 16-30; 42(8):471-7. PubMed ID: 16625509
[TBL] [Abstract][Full Text] [Related]
14. Effect of galantamine on the human alpha7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity.
Texidó L; Ros E; Martín-Satué M; López S; Aleu J; Marsal J; Solsona C
Br J Pharmacol; 2005 Jul; 145(5):672-8. PubMed ID: 15834443
[TBL] [Abstract][Full Text] [Related]
15. [Nicotinic Receptor, galantamine and Alzheimer disease].
Arroyo G; Aldea M; Fuentealba J; García AG
Rev Neurol; 2002 Jun 1-15; 34(11):1057-65. PubMed ID: 12134305
[TBL] [Abstract][Full Text] [Related]
16. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
17. Acetylcholinesterase inhibitors as Alzheimer therapy: from nerve toxins to neuroprotection.
Singh M; Kaur M; Kukreja H; Chugh R; Silakari O; Singh D
Eur J Med Chem; 2013; 70():165-88. PubMed ID: 24148993
[TBL] [Abstract][Full Text] [Related]
18. Acetylcholinesterase inhibitors: novel activities of old molecules.
Racchi M; Mazzucchelli M; Porrello E; Lanni C; Govoni S
Pharmacol Res; 2004 Oct; 50(4):441-51. PubMed ID: 15304241
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
Duysen EG; Li B; Darvesh S; Lockridge O
Toxicology; 2007 Apr; 233(1-3):60-9. PubMed ID: 17194517
[TBL] [Abstract][Full Text] [Related]
20. The acetylcholinesterase (AChE) inhibitor and anti-Alzheimer drug donepezil interacts with human erythrocytes.
Zambrano P; Suwalsky M; Jemiola-Rzeminska M; Strzalka K; Sepúlveda B; Gallardo MJ; Aguilar LF
Biochim Biophys Acta Biomembr; 2019 Jun; 1861(6):1078-1085. PubMed ID: 30904408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
